AURA (Aura Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AURA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Susan Abu-Absi | Chief Operating Officer | A | — | — |
| 2026-09-01 | Erica Kratz | Chief Reg. & Quality Officer | A | — | — |
| 2026-09-01 | Julie Person | Chief People Officer | A | — | — |
| 2026-09-01 | Janet Jill Hopkins | Chief Medical Officer | A | — | — |
| 2026-09-01 | Amy Elazzouzi | SVP, Finance & PAO | A | — | — |
| 2026-07-08 | Jeremy Bender | Director | A | — | — |
| 2026-07-01 | Conor Kilroy | See Remarks | A | — | — |
| 2026-06-16 | Anthony S Gibney | See Remarks | Sell | — | — |
| 2026-06-15 | Antony C. Mattessich | Director | A | — | — |
| 2026-06-15 | Teresa Marie Bitetti | Director | A | — | — |
| 2026-06-15 | Sapna Srivastava | Director | A | — | — |
| 2026-06-15 | David Michael Johnson | Director | A | — | — |
| 2026-05-19 | Natalie C. Holles | See Remarks | A | — | — |
| 2026-05-11 | DAVID E. GOEL | 10%+ Owner | Sell | — | — |
| 2026-04-16 | Conor Kilroy | See Remarks | Sell | — | — |
| 2026-03-03 | Janet Jill Hopkins | Chief Medical Officer | A | — | — |
| 2026-03-03 | Anthony S Gibney | See Remarks | A | — | — |
| 2026-03-03 | Amy Elazzouzi | Senior Vice President, Finance | A | — | — |
| 2026-03-03 | Pinos Elisabet de los | See Remarks | A | — | — |
| 2026-03-03 | Mark Plavsic | Chief Technology Officer | A | — | — |
| 2026-03-03 | Conor Kilroy | See Remarks | A | — | — |
| 2026-02-17 | Conor Kilroy | See Remarks | Sell | — | — |
| 2026-02-17 | Amy Elazzouzi | Senior Vice President, Finance | Sell | — | — |
| 2026-02-17 | Pinos Elisabet de los | See Remarks | Sell | — | — |
| 2026-02-17 | Janet Jill Hopkins | Chief Medical Officer | Sell | — | — |
| 2026-02-17 | Mark Plavsic | Chief Technology Officer | Sell | — | — |
| 2026-01-20 | Amy Elazzouzi | Senior Vice President, Finance | Sell | — | — |
| 2026-01-20 | Pinos Elisabet de los | See Remarks | Sell | — | — |
| 2025-11-17 | Janet Jill Hopkins | Chief Medical Officer | Sell | — | — |
| 2025-10-29 | Amy Elazzouzi | Senior Vice President, Finance | Sell | — | — |
| 2025-10-29 | Pinos Elisabet de los | See Remarks | Sell | — | — |
| 2025-10-16 | Mark Plavsic | Chief Technology Officer | Sell | — | — |
| 2025-08-18 | Amy Elazzouzi | Senior Vice President, Finance | MIXED | — | — |
| 2025-06-18 | Antony C. Mattessich | Director | A | — | — |
| 2025-06-18 | Sapna Srivastava | Director | A | — | — |
| 2025-06-18 | David Michael Johnson | Director | A | — | — |
| 2025-06-04 | Anthony S Gibney | See Remarks | A | — | — |
| 2025-06-04 | Pinos Elisabet de los | See Remarks | MIXED | — | — |
| 2025-05-20 | Anthony S Gibney | See Remarks | MIXED | — | — |
| 2025-05-20 | David Michael Johnson | Director | Buy | — | — |
| 2025-04-16 | Conor Kilroy | See Remarks | Sell | — | — |
| 2025-04-16 | Amy Elazzouzi | Senior Vice President, Finance | Sell | — | — |
| 2025-04-02 | Teresa Marie Bitetti | Director | A | — | — |
| 2025-02-18 | Mark Plavsic | Chief Technology Officer | Sell | — | — |
| 2025-02-18 | Pinos Elisabet de los | See Remarks | Sell | — | — |
| 2025-02-18 | Amy Elazzouzi | Senior Vice President, Finance | Sell | — | — |
| 2025-02-18 | Janet Jill Hopkins | Chief Medical Officer | Sell | — | — |
| 2025-02-04 | Amy Elazzouzi | Senior Vice President, Finance | A | — | — |
| 2025-02-04 | Pinos Elisabet de los | See Remarks | A | — | — |
| 2025-02-04 | Conor Kilroy | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,922,870 | — |
| — | See Remarks | 1,153,962 | — |
| — | See Remarks | 703,578 | — |
| — | Chief Medical Officer | 380,190 | — |
| — | Director | 269,167 | — |
| — | See Remarks | 265,354 | — |
| — | Chief Technology Officer | 243,736 | — |
| — | See Remarks | 232,693 | — |
| — | Chief Financial Officer | 151,776 | — |
| — | SVP, Finance & PAO | 143,600 | — |
| — | Chief Operating Officer | 134,513 | — |
| — | Chief People Officer | 107,611 | — |
| — | Chief Reg. & Quality Officer | 100,885 | — |
| — | See Remarks | 58,703 | — |
| — | Chief Operating Officer | 58,635 | — |
| — | 10%+ Owner | 54,065 | — |
| — | Director | 38,500 | — |
| — | Director | 38,500 | — |
| — | Director | 36,000 | — |
| — | Director | 30,000 | — |
| — | Chief Business Officer | 8,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AURA quote page; the site-wide leaderboard is on the insider transactions hub.